Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro

BMC Complementary and Alternative Medicine

Volumn 14, Issue , 2014, Pages

  Weissenstein, Ulrike ^a   Kunz, Matthias ^a   Urech, Konrad ^a   Baumgartner, Stephan ^a,b  

^a Society for Cancer Research   (Switzerland)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Chemotherapy; Cytostasis; Cytotoxicity; Drug interactions; Iscador; Mistletoe (Viscum album L.)

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; MITOXANTRONE; VISCUM ALBUM EXTRACT; CYTOSTATIC AGENT; DEOXYCYTIDINE; PLANT EXTRACT; TAXOID;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CYTOSTASIS; CYTOTOXICITY; HERB DRUG INTERACTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LUNG CARCINOMA; PANCREAS ADENOCARCINOMA; PROSTATE CARCINOMA; VISCUM ALBUM; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; MALE; MEDICINAL PLANT; NEOPLASMS; PATHOLOGY; STANDARDS; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYTOSTATIC AGENTS; DEOXYCYTIDINE; DOXORUBICIN; HERB-DRUG INTERACTIONS; HUMANS; MALE; MITOXANTRONE; NEOPLASMS; PLANT EXTRACTS; PLANTS, MEDICINAL; TAXOIDS; VISCUM ALBUM;

EID: 84892145189     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-14-6     Document Type: Article

References (48)

1. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?. Clin Cancer Res 2007, 13(24):7280-7287. 10.1158/1078-0432.CCR-07-2141, 18094408.
2. Cheng KC, Li YX, Cheng JT. The use of herbal medicine in cancer-related anorexia/ cachexia treatment around the world. Curr Pharm Des 2012, 18(31):4819-4826. 10.2174/138161212803216979, 22632862.
3. Engdal S, Steinsbekk A, Klepp O, Nilsen OG. Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer 2008, 16(7):763-769. 10.1007/s00520-007-0371-3, 18196289.
4. Harmsma M, Ummelen M, Dignef W, Tusenius KJ, Ramaekers FC. Effects of mistletoe (Viscum album L.) extracts Iscador on cell cycle and survival of tumor cells. Arzneimittelforschung 2006, 56(6A):474-482.
5. Kovacs E, Link S, Toffol-Schmidt U. Cytostatic and cytocidal effects of mistletoe (Viscum album L.) quercus extract Iscador. Arzneimittelforschung 2006, 56(6A):467-473.
6. Seifert G, Jesse P, Laengler A, Reindl T, Luth M, Lobitz S, Henze G, Prokop A, Lode HN. Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer letters 2008, 264(2):218-228. 10.1016/j.canlet.2008.01.036, 18314258.
7. Urech K, Schaller G, Jaggy C. Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 2006, 56(6A):428-434.
8. Park WB, Lyu SY, Kim JH, Choi SH, Chung HK, Ahn SH, Hong SY, Yoon TJ, Choi MJ. Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis. Cancer Biother Radiopharm 2001, 16(5):439-447. 10.1089/108497801753354348, 11776761.
9. Elluru SR, van Huyen J-P D, Wootla B, Delignat S, Prost F, Negi V-S, Kaveri SV. Tumor regressive effects of Viscum album preparations - exploration of immunomodulatory mechanisms. Medicina 2007, 67(Supl. II):85-89.
10. Schink M, Troger W, Dabidian A, Goyert A, Scheuerecker H, Meyer J, Fischer IU, Glaser F. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial. Forschende Komplementarmedizin (2006) 2007, 14(1):9-17. 10.1159/000098135, 17341882.
11. Bussing A. Immune modulation using mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 2006, 56(6A):508-515.
12. Heinzerling L, von Baehr V, Liebenthal C, von Baehr R, Volk HD. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol 2006, 26(4):347-359. 10.1007/s10875-006-9023-5, 16705487.
13. Liu B, Bian HJ, Bao JK. Plant lectins: potential antineoplastic drugs from bench to clinic. Cancer Lett 2010, 287(1):1-12. 10.1016/j.canlet.2009.05.013, 19487073.
14. Engdal S, Nilsen OG. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica 2008, 38(6):559-573. 10.1080/00498250801986969, 18570158.
15. Ostermann T, Raak C, Bussing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC cancer 2009, 9:451. 10.1186/1471-2407-9-451, 2804713, 20021637.
16. Grossarth-Maticek R, Ziegler R. Randomised and non-randomised prospective controlled cohort studies in matched-pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res 2006, 11(11):485-495.
17. Bussing A, Raak C, Ostermann T. Quality of life and related dimensions in cancer patients treated with mistletoe extract (iscador): a meta-analysis. Evid Based Complement Alternat Med 2012, 2012:219402. 3124023, 21747894.
18. Friedel WE, Matthes H, Bock PR, Zanker KS. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol 2009, 7(4):137-145.
19. Troger W, Zdrale Z, Stankovic N, Matijasevic M. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with viscum album (L.) extract to chemotherapy alone. Breast Cancer (Auckl) 2012, 6:173-180. 3493140, 23150723.
20. Carmer SG, Swanson MR. An evaluation of ten pairwise multiple comparison procedures by Monte Carlo methods. J Am Stat Assoc 1973, 68:66-74.
21. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003, 2(6):549-555.
22. Engdal S, Nilsen OG. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res 2009, 23(7):906-912. 10.1002/ptr.2750, 19170155.
23. Doehmer J, Eisenbraun J. Assessment of extracts from mistletoe (Viscum album) for herb-drug interaction by inhibition and induction of cytochrome P450 activities. Phytother Res 2012, 26(1):11-17. 10.1002/ptr.3473, 21538623.
24. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, AWMF-Register-Nummer: 032 - 045OL. [http://www.awmf.org/uploads/tx_szleitlinien/032-045OL_k_S3__Brustkrebs_Mammakarzinom_Diagnostik_Therapie_Nachsorge_2012-07.pdf].
25. Exokrines Pankreaskarzinom, S3-Leitlinie im Auftrag der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Krebsgesellschaft (DKG). [http://www.krebsgesellschaft.de/download/s3-leitlinie_exokrines_pankreaskarzinom.pdf].
26. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, AWMF-Register-Nummer (043-022OL). [http://www.awmf.org/uploads/tx_szleitlinien/043-022OLk_S3_Prostatakarzinom_2011.pdf].
27. Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer, Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version. [http://www.awmf.org/uploads/tx_szleitlinien/020-007k_S3_Lungenkarzinom_Kurzfassung_2011-08.pdf].
28. Galun D, Tröger W, Reif M, Schumann A, Stankovic N, Milicevic M. Mistletoe extract therapy versus no antineoplastic therapy in patients with locally advanced or metastatic pancreatic cancer: a randomized clinical phase III trial on overall survival (abstract). Ann Oncol 2012, 23(Supplement 9):712P.
29. Fachinformation des Arzneimittel-Kompendium der Schweiz®. 2007, [http://www.designandweb.net/01_MyHP/Fachinformation_Iscador.pdf ].
30. Janssen O, Scheffler A, Kabelitz D. In vitro effects of mistletoe extracts and mistloetoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneim Forsch / Drug Res 1993, 43:1221-1227.
31. Endo Y, Tsurugi K, Franz H. The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes. The RNA N-glycosidase activity of the protein. FEBS Lett 1988, 231(2):378-380. 10.1016/0014-5793(88)80853-6, 3360143.
32. Büssing A. Induction of apoptosis by the mistletoe lectins. A review on the mechanisms of cytotoxicity mediated by Viscum album L. Apoptosis 1996, 1(1):25-32.
33. Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S. Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res 1999, 59(9):2083-2090.
34. Kovacs E. Investigation of the proliferation, apoptosis/necrosis, and cell cycle phases in several human multiple myeloma cell lines. Comparison of Viscum album QuFrF extract with vincristine in an in vitro model. TheScientificWorldJournal 2010, 10:311-320.
35. Mockel B, Schwarz T, Zinke H, Eck J, Langer M, Lentzen H. Effects of mistletoe lectin I on human blood cell lines and peripheral blood cells. Cytotoxicity, apoptosis and induction of cytokines. Arzneimittelforschung 1997, 47(10):1145-1151.
36. Bussing A, Schaller G, Pfuller U. Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L. Anticancer Res 1998, 18(6A):4291-4296.
37. Siegle I, Fritz P, McClellan M, Gutzeit S, Murdter TE. Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. Anticancer Res 2001, 21(4A):2687-2691.
38. Orth JD, Tang Y, Shi J, Loy CT, Amendt C, Wilm C, Zenke FT, Mitchison TJ. Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate. Mol Cancer Ther 2008, 7(11):3480-3489. 10.1158/1535-7163.MCT-08-0684, 2597169, 18974392.
39. Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004, 7(5):637-651. 10.1016/j.devcel.2004.09.002, 15525526.
40. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer cell 2008, 14(2):111-122. 10.1016/j.ccr.2008.07.002, 18656424.
41. Orth JD, Loewer A, Lahav G, Mitchison TJ. Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Mol Biol Cell 2012, 23(4):567-576. 10.1091/mbc.E11-09-0781, 3279386, 22171325.
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
43. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108(2):153-164. 10.1016/S0092-8674(02)00625-6, 11832206.
44. Kienle GS, Kiene H. Review article: influence of viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 2010, 9(2):142-157. 10.1177/1534735410369673, 20483874.
45. Matthes H, Friedel WE, Bock PR, Zanker KS. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer. Curr Mol Med 2010, 10(4):430-439. 10.2174/156652410791317057, 20455850.
46. Burkhart J, Walchli C, Heusser P, Weissenstein U, Baumgartner S, Andres AC. In vitro investigation into the potential of a mistletoe extract to alleviate adverse effects of cyclophosphamide. Altern Ther Health Med 2010, 16(3):40-48.
47. Kovacs E. The in vitro effect of Viscum album (VA) extract on DNA repair of peripheral blood mononuclear cells (PBMC) in cancer patients. Phytother Res 2002, 16(2):143-147. 10.1002/ptr.920, 11933116.
48. Bussing A, Regnery A, Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett 1995, 94(2):199-205. 10.1016/0304-3835(95)03850-V, 7634248.